The estimated Net Worth of Willie A Deese is at least $3.54 Million dollars as of 24 May 2017. Mr. Deese owns over 1,220 units of G1 Therapeutics stock worth over $226,623 and over the last 10 years he sold GTHX stock worth over $2,734,000. In addition, he makes $580,322 as Independent Director at G1 Therapeutics.
Mr. Deese GTHX stock SEC Form 4 insider trading
Willie has made over 17 trades of the G1 Therapeutics stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 1,220 units of GTHX stock worth $27,645 on 24 May 2017.
The largest trade he’s ever made was exercising 135,864 units of G1 Therapeutics stock on 11 February 2015 worth over $5,494,340. On average, Willie trades about 6,443 units every 31 days since 2009. As of 24 May 2017 he still owns at least 10,001 units of G1 Therapeutics stock.
You can see the complete history of Mr. Deese stock trades at the bottom of the page.
Willie Deese biography
Willie A. Deese is Independent Director of the company. He has served as a member of our Board of Directors since June 2018. Mr. Deese retired from Merck & Co., Inc. on June 1, 2016 after serving as Executive Vice President since 2008 and President of the Merck Manufacturing Division since 2005. He was also a member of Merck’s Executive Committee. Mr. Deese originally joined Merck in 2004 as the company’s Senior Vice President of Global Procurement. Previously, Mr. Deese served as Senior Vice President of Global Procurement and Logistics at GlaxoSmithKline and as Senior Vice President of Procurement at SmithKlineBeecham. Mr. Deese previously served as a member of the Board of Trustees of North Carolina A&T State University from 2007 to 2015, including as its chair from 2011 to 2013. Mr. Deese is also a member of the boards of directors of CDK Global Inc., Public Service Enterprise Group, Inc., and DENTSPLY SIRONA Inc. Mr. Deese holds an M.B.A. from Western New England College and a B.A. in Business Administration from North Carolina A&T State University.
What is the salary of Willie Deese?
As the Independent Director of G1 Therapeutics, the total compensation of Willie Deese at G1 Therapeutics is $580,322. There are 8 executives at G1 Therapeutics getting paid more, with John Demaree having the highest compensation of $7,466,410.
How old is Willie Deese?
Willie Deese is 63, he’s been the Independent Director of G1 Therapeutics since 2018. There are 3 older and 11 younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics, Inc. is Fredric Eshelman, 70, who is the Independent Director.
What’s Willie Deese’s mailing address?
Willie’s mailing address filed with the SEC is 13320 BALLANTYNE CORPORATE PLACE, , CHARLOTTE, NC, 28277.
Insider trading at G1 Therapeutics
Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.
What does G1 Therapeutics do?
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
What does G1 Therapeutics’s logo look like?
Complete history of Mr. Deese stock trades at CDK Global, Dentsply Sirona, G1 Therapeutics, Merck & Co, and Public Service Enterprise
G1 Therapeutics executives and stock owners
G1 Therapeutics executives and other stock owners filed with the SEC include:
- John Demaree, Chief Commercial Officer
- James Hanson, General Counsel
- Terry Murdock, Chief Operating Officer
- Mark Velleca, President, Chief Executive Officer, Director
- Garry Nicholson, Independent Chairman of the Board
- Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
- Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
- Cynthia Schwalm, Independent Director
- Willie Deese, Independent Director
- Seth Rudnick, Independent Director
- Glenn Muir, Independent Director
- Fredric Eshelman, Independent Director
- Andrew Witty, Independent Director
- Jeff Macdonald, Head of Investor Relations/Public Relations
- Jennifer Moses, Vice President – Finance and Accounting
- Jay Strum, Chief Scientific Officer
- Clay Hatteras Venture Advis…,
- Capital Management, Llcra C…,
- Christy L Shaffer, Director
- Ventures, Inc. Med Immune, 10% owner
- Ventures, Llc Eshelman, 10% owner
- Clay Hatteras Venture Advis…,
- Mark Avagliano, Chief Business Officer
